Laurence A. Turka M.D. Net Worth

The estimated Net Worth of Laurence A. Turka is at least $707 Tysiąc dollars as of 29 January 2023. Mr Turka owns over 16,063 units of Rubius Therapeutics Inc stock worth over $1,742 and over the last 5 years he sold RUBY stock worth over $0. In addition, he makes $704,937 as Chief Scientific Officer and Head of Research & Translational Medicine at Rubius Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr D RUBY stock SEC Form 4 insiders trading

Mr has made over 2 trades of the Rubius Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 16,063 units of RUBY stock worth $1,333 on 29 January 2023.

The largest trade he's ever made was exercising 16,063 units of Rubius Therapeutics Inc stock on 29 January 2023 worth over $1,333. On average, Mr trades about 5,875 units every 91 days since 2020. As of 29 January 2023 he still owns at least 20,984 units of Rubius Therapeutics Inc stock.

You can see the complete history of Mr Turka stock trades at the bottom of the page.

Mr. Laurence A. Turka M.D. biography

Laurence A. Turka M.D. is the Chief Scientific Officer and Head of Research & Translational Medicine at Rubius Therapeutics Inc.

What is the salary of Mr D?

As the Chief Scientific Officer and Head of Research & Translational Medicine of Rubius Therapeutics Inc, the total compensation of Mr D at Rubius Therapeutics Inc is $704,937. There are 4 executives at Rubius Therapeutics Inc getting paid more, with Pablo Cagnoni having the highest compensation of $1,721,130.

How old is Mr D?

Mr D is 63, he's been the Chief Scientific Officer and Head of Research & Translational Medicine of Rubius Therapeutics Inc since . There are 3 older and 15 younger executives at Rubius Therapeutics Inc. The oldest executive at Rubius Therapeutics Inc is Michael Rosenblatt, 69, who is the Independent Director.

What's Mr D's mailing address?

Laurence's mailing address filed with the SEC is C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY ST., SUITE 300, CAMBRIDGE, MA, 02139.

Insiders trading at Rubius Therapeutics Inc

Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over $2,165,279 worth of Rubius Therapeutics Inc stock and bought 305,000 units worth $6,624,680 . The most active insiders traders include Noubar Afeyan, Roger Pomerantz oraz Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $2,709. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth $1,350.

What does Rubius Therapeutics Inc do?

developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.

Complete history of Mr Turka stock trades at Rubius Therapeutics Inc

Rubius Therapeutics Inc executives and stock owners

Rubius Therapeutics Inc executives and other stock owners filed with the SEC include:

• Pablo Cagnoni,
  President, Chief Executive Officer, Director
• Maiken Keson-Brookes,
  Chief Legal Officer, Corporate Secretary
• Dr. Pablo J. Cagnoni M.D., Ph.D.,
  CEO, Pres & Director
• David Epstein,
  Chairman of the Board
• Laurence A. Turka M.D.,
  Chief Scientific Officer and Head of Research & Translational Medicine
• Natalie Holles,
  Independent Director
• David R. Epstein B.Sc., M.B.A.,
  Exec. Chairman
• Dannielle Appelhans,
  Chief Operating Officer
• Anne Prener,
  Independent Director
• Jonathan Symonds,
  Independent Director
• Francis Cuss,
  Independent Director
• Catherine Sohn,
  Independent Director
• Noubar Afeyan,
  Independent Director
• Michael Rosenblatt,
  Independent Director
• Lori Melancon,
  IR Contact Officer
• Christina Coughlin,
  Chief Medical Officer
• Greg ..,
  Chief Quality Officer
• Laurence Turka,
  Chief Scientific Officer
• Kris Elverum,
  Senior Vice President - Business Development and Strategy
• Jose Carmona,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
• Jill Murray,
  VP & Head of HR
• Marissa Hanify,
  Director of Corp. Communications
• Maiken Keson-Brookes,
  Chief Legal Officer & Corp. Sec.
• Elhan Webb C.F.A.,
  VP of Investor Relations
• Mark J. Hernon,
  Chief Information Officer
• Spencer Fisk,
  Sr. VP & Chief Technical Operations Officer
• Jose I. Carmona,
  CFO, Principal Accounting Officer & Treasurer
• Ventures Fund Iv General Pa...,
  
• Susanne Schaffert,
  Director
• Robert Langer,
  Director
• Roger Pomerantz,
  Director
• Ventures Fund Iv General Pa...,
  
• Torben Straight Nissen,
  President
• Christopher L. Carpenter,
  Chief Medical Officer
• Dannielle Appelhans,
  CEO and President